149 related articles for article (PubMed ID: 21951530)
1. A zebrafish model for VHL and hypoxia signaling.
van Rooijen E; Santhakumar K; Logister I; Voest E; Schulte-Merker S; Giles R; van Eeden F
Methods Cell Biol; 2011; 105():163-90. PubMed ID: 21951530
[TBL] [Abstract][Full Text] [Related]
2. Zebrafish mutants in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia.
van Rooijen E; Voest EE; Logister I; Korving J; Schwerte T; Schulte-Merker S; Giles RH; van Eeden FJ
Blood; 2009 Jun; 113(25):6449-60. PubMed ID: 19304954
[TBL] [Abstract][Full Text] [Related]
3. Zebrafish as a model for von Hippel Lindau and hypoxia-inducible factor signaling.
Kim HR; Greenald D; Vettori A; Markham E; Santhakumar K; Argenton F; van Eeden F
Methods Cell Biol; 2017; 138():497-523. PubMed ID: 28129856
[TBL] [Abstract][Full Text] [Related]
4. von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish.
van Rooijen E; Voest EE; Logister I; Bussmann J; Korving J; van Eeden FJ; Giles RH; Schulte-Merker S
Dis Model Mech; 2010; 3(5-6):343-53. PubMed ID: 20335444
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological HIF2α inhibition improves VHL disease-associated phenotypes in zebrafish model.
Metelo AM; Noonan HR; Li X; Jin Y; Baker R; Kamentsky L; Zhang Y; van Rooijen E; Shin J; Carpenter AE; Yeh JR; Peterson RT; Iliopoulos O
J Clin Invest; 2015 May; 125(5):1987-97. PubMed ID: 25866969
[TBL] [Abstract][Full Text] [Related]
6. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
8. von Hippel-Lindau gene plays a role during zebrafish pronephros development.
Chen YH; Chang CF; Lai YY; Sun CY; Ding YJ; Tsai JN
In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1023-32. PubMed ID: 26194803
[TBL] [Abstract][Full Text] [Related]
9. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide mapping of Hif-1α binding sites in zebrafish.
Greenald D; Jeyakani J; Pelster B; Sealy I; Mathavan S; van Eeden FJ
BMC Genomics; 2015 Nov; 16():923. PubMed ID: 26559940
[TBL] [Abstract][Full Text] [Related]
11. Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL).
Liu X; Cai X; Hu B; Mei Z; Zhang D; Ouyang G; Wang J; Zhang W; Xiao W
J Biol Chem; 2016 Dec; 291(49):25692-25705. PubMed ID: 27777301
[TBL] [Abstract][Full Text] [Related]
12. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
14. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.
Hickey MM; Lam JC; Bezman NA; Rathmell WK; Simon MC
J Clin Invest; 2007 Dec; 117(12):3879-89. PubMed ID: 17992257
[TBL] [Abstract][Full Text] [Related]
17. Von hippel-lindau disease: a genetic and clinical review.
Haddad NM; Cavallerano JD; Silva PS
Semin Ophthalmol; 2013; 28(5-6):377-86. PubMed ID: 24138046
[TBL] [Abstract][Full Text] [Related]
18. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
19. Von Hippel-Lindau syndrome: molecular mechanisms of the disease.
Calzada MJ
Clin Transl Oncol; 2010 Mar; 12(3):160-5. PubMed ID: 20231120
[TBL] [Abstract][Full Text] [Related]
20. Systemic VHL gene functions and the VHL disease.
Bader HL; Hsu T
FEBS Lett; 2012 Jun; 586(11):1562-9. PubMed ID: 22673568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
